Tampilkan postingan dengan label Washington Post. Tampilkan semua postingan
Tampilkan postingan dengan label Washington Post. Tampilkan semua postingan

Senin, 07 Agustus 2017

Bringing down pharmaceutical costs

Bringing down pharmaceutical costs


Today's Managing Health Care Costs Number is  250%

One area of bipartisan agreement is the desire to lower pharmaceutical prices.   As always, there are good ideas with downsides, bad ideas with upsides, and many ideas that are likely to  have unanticipated consequences.   Annual prescription drug costs are expected to increase to $597 billion by 2025- a 250% increase from 2007, so there is a real imperative to address pharmaceutical costs. 

Among the ideas that are being discussed:

  1. Ease regulatory burden to allow faster generics to market. 
    The real problem here has generally been litigation from incumbent brand name products and lack of competition for non-blockbuster generics, most of which have only 1 or 2 manufacturers - leaving them vulnerable to steep price increases.  Let's make it harder to take legal steps to block new generics, easier to get approval for biosimilars, and allow importation of generics from other countries with good regulatory schemes when there is a shortage.
     
  2. Allow 'value based pricing.'
    No one is preventing value based pricing now- but we should think hard about whether this is really what we want.   Airlines use value based pricing (so that business travelers not staying over a Saturday night pay higher prices).   Some pharmaceutical companies want to be able to charge different prices based on the indication for a drug - but this is likely to lead to higher overall costs (and huge administrative headaches).  Her's a pretty positive assessment of  indication specific pricing from ICER (2015), and here's a perspective from New England Journal of Medicine (2017) pointing to likely higher overall costs. Reports from countries that implemented warrantees are disappointing; these were hard to reconcile and probably led to higher prices. A report from Propublica  begins:

More than a decade ago, Italy tried a novel approach to help bring down drug costs: asking pharmaceutical companies to return money to the national health system if some of their medicines failed to work as expected. The effort largely flopped

  1. "March in" and demand that patent-holders offer drugs for less, or seize the patent
    Some countries like Brazil and India have effectively done this- but they are much smaller markets than the US and they tend to be home to generic and not brand manufacturers.   This might be a more effective threat than actual policy.  Some Democrats have suggested that the NIH should exercise its 'march in' rights. Many think this would lead to decreased investment in pharma and less innovation - and such a move seems unlikely in an Administration seeking to diminish the role of government.
     
  2. Allow Medicare to negotiate drug prices
    Right now Medicare Part D is administered through thousands (!) of different plans each of which negotiates with the pharmaceutical industry.  That kind of fragmentation leads to higher prices for Medicare, the largest purchaser of drugs in the country.   Medicare pays more than the Veterans Administration or Medicaid for drugs.  It's hard to imagine disassembling the current Medicare Part D system in the next few years - although it would be easy to imagine some central negotiation for high cost medications that could be excluded from the Medicare Part D plans.
     
  3. Stop drug company direct to consumer advertising
    This would make TV viewing much more pleasurable - but the Supreme Court has decided that commercial speech is protected by the First Amendment, so this would require a constitutional amendment.
     
  4. Direct the FDA to consider cost effectiveness when it approves new medications
    This would require a new statute and new enabling regulations. Countries like the UK which have this in place have found that it does lower access to some new innovative drugs, and this is unpopular.  Perhaps this isn't unpopular at the level of fictional "death panels," but it would be hard to see such legislation gaining broad traction in the next few years.
     
  1. Mandate generic substitution
    Fourteen states mandate that a generic be dispensed where available unless the physician explicitly orders a brand name, and this dramatically increases generic substitution rate.  49 states allow pharmacist generic substitution based on pharmacist discretion - and only Oklahoma prohibits even this.  This battle must be fought state by state, and a small amount of lobbying goes a long way in most state legislatures.
     
  1. Provider risk sharing
    Physicians write prescriptions - and they would pay much more attention to the cost of drugs if their organizations bore financial responsibility for drug costs.  Providers do take risk for drug spending in some accountable care or bundled payment arrangements.  Provider risk sharing could also lead to physicians failing to prescribe valuable but expensive drugs, or "dumping" of patients with known chronic diseases that have expensive drug treatment. 

I'm not confident we'll lower pharmaceutical prices a lot over the next few years- especially given the new genomic drugs in the offing.  And I'm worried that the cost savings from generics might diminish through consolidation in that industry. But I'm heartened by the discussion and the bipartisan concern. Elements of the approach to lowering drug cost inflation that are being discussed now could serve as the foundation to lower costs in the years to come.
  

Kamis, 25 Mei 2017

23 million to lose insurance under AHCA


Today's Managing Health Care Costs Number is 23 million



The Congressional Budget Office report on the American Health Care Act dropped last night at the end of the East Coast business day -and the news is great according to Paul Ryan.


“This CBO report again confirms that the American Health Care Act achieves our mission: lowering premiums and lowering the deficit,” Ryan said in a statement. “It is another positive step toward keeping our promise to repeal and replace Obamacare.”

Pretty much everyone else with a brain demurs.

Highlights of the CBO analysis:

  • 23 million will lose their health insurance by 2026
  • 14 million would lose Medicaid coverage (and that's before the additional cuts in the Trump 2018 budget proposal
  • 1/6 of Americans live in areas where the unstable individual market would make purchase of insurance prohibitively expensive for those with preexisting illnesses - mainly in states that waived essential benefits.
  • 1 in 5 Americans under 65 will be uninsured by 2026
  • Lower premiums are purely driven by loss of coverage by older and sicker people, and by skimpier "coverage."   (Plans without maternity, mental health, and inpatient care are not really coverage, are they?)
  • The overwhelming majority of health care cuts fund tax cuts for the rich, for drug companies, and for insurers.  (Total tax cuts are $661 billion- while deficit reduction is only $119 billion)



Source

Source


Source 



Senin, 22 Mei 2017

We're Number 33!!


Today's Managing Health Care Costs Number is 33 (out of 195)




The World Health Organization (WHO) ranked countries for their health outcomes in 2000, and at the time the United States ranked 37 - between Costa Rica and Slovenia.  Many argued that the WHO methodology was unsound, which it was.    Rankings like this were subject to reporting accuracy and definitional differences from country to country! Tiny countries (Andorra anyone) often were advantaged in the ranking! Technology wasn't adequately valued!  Rank orders give no sense of significant differences between countries with similar rankings! Could France really be number 1?!

The WHO ranking might have been controversial -but there are a host of purely objectives by which the US lags the rest of the developed world, even as we spend more dollars on health care than any other nation.   The New England Journal noted that in 2006 we were 39th for infant mortality, 43rd for adult female mortality, 42nd for adult male mortality, and 36th for life expectancy.  We are the only developed country with rising maternal mortality.  Propublica is currently running a series of articles on this.  

The WHO backed off - and it's been over a decade and a half and it hasn't tried to repeat this ranking.

The Institute for Health Metrics Evaluation, funded by the Bill and Melinda Gates Foundation,  has stepped into the breach in last week's Lancet.  IHME reviewed data from the Global Burden of Disease database, using 1995 and 2015 iterations, and evaluated how effective each country is in preventing preventable disease.  

The good news is that our score on the Health Access and Quality Index (HAQ) is improved.   We have risen about 7 points, and decreased the difference between our observed and the HAQ researchers would expect based on sociodevelopment index.    We have moved up to #33 now - between Estonia and Montenegro.   Sure, the Scandinavian countries and Western European democracies exceed the US.   But we also score lower than Greece (#17) and Slovenia (#16). Lebanon is #34, lagging the US by just a point.  And refugees in Lebanon make up a quarter of the population!

Rank orders are always flawed - and a small difference in rank can mean a lot of real difference or very little real difference.  But the US is clearly lagging other developed countries in improving access and quality in health care.   We're also on the precipice to make health care access dramatically worse.  We can certainly do better.  This study also only looked at access and quality -and did not look at value.  Given our high unit prices and focus on expensive technology, a "value" ranking could easily leave the US out of the top quartile.

H/T to Washington Post for pointing me to the Lancet article, which is not behind a paywall.

This shows that 1995 score is very closely related to 2015 score - and you can see that developed countries score highest.  Note that virtually all countries improved over this 20 year period- as they are to the left of the diagonal line.  Note that the confidence intervals are also much larger for the less developed countries. 

These are the elements where the US scores less than 70.   Source of both graphics is the Lancet article 

Rabu, 12 April 2017

Trump budget a roadmap to worsening health

Source (Washington Post)

The May issue of the American Public Health Association reviews the budget cuts which it sways would be "devastating to public health."  (This issue is not yet on line - this will be the URL when it is uploaded).   I've correlated this with the reporting from a month ago in the Washington Post.

It's important that we recognize that the failure of the AHCA and "repeal and replace" doesn't mean that public health is by any means safe.

  • Health and Human Services: $15.1 billion cut (18%)
  • Centers for Disease Control and Prevention: additional 12% cut if the ACA's Prevention and Public Health Fund is eliminated.  The Administration promises $300 million for Zika research - but that will taken from somewhere else in the CDC budget.
  • National Institutes of Health $5.8 billion (18%).  That's less cancer research - and fewer new basic science discoveries
  • Environmental Protection Agency  $2.5 billion cut (31%).  This threatens Superfund site cleanups and drinking water inspections and will decimate enforcement efforts
  • Department of Labor $2.6 billion cut (21%) eliminating grants that support training in occupational health
  • Department of Agriculture, $4.7 billion cut (21%). The administration pledges not to cut back on food safety inspections -but who believes that?  The Administration pledges to fully fund SNAP (aka food stamps), although the actual budget there is lower due to the improved economy.
  • Department of Energy $1.7billion cut (6%)  Programs to decrease carbon emissions are wiped out, and there are new dollars for nuclear disposal.

This is to say nothing of the efforts to further trim a social safety net that is already more threadbare than that of most of the developed world.  

Sometimes we in the health care world spend so much time thinking about how to improve the medical care delivery system that we can have a blind spot about how little of health care outcomes is driven by the medical care system -and how much is driven by socioeconomic factors, environment and behavior.  Economic policies that lead to increased poverty and income disparities will also worsen health in the US. The Trump Administration is disassembling the levers that government has used to help improve the overall health of our communities.   We must argue as strenuously against these ill-advised budget cuts as we did against the reckless attempt to repeal the Affordable Care Act.

Kamis, 01 Desember 2016

Mismatch between opioid risk and needle exchanges

Deaths from Drug Overdoses and Automobile Accidents, US (annual)
Source (Boston Globe)

Opioid deaths are one reason that the US has been less successful at increasing life expectancy than other high income countries.  Drug abuse deaths -mostly from opiods, surpassed motor vehicle accidents as a cause of deaths in the US last year.  These deaths are disproportionately concentrated in distressed communities - including inner cities (the ones that haven't been gentrified) and poor rural areas, especially those which have suffered from manufacturing collapse.


Even these statistics about the opioid epidemic and its impact are don't tell the whole depressing story.   Many of the premature deaths among those addicted come from infectious diseases related to needle use - and these are not likely to be counted in the graphic above.   I blogged about a disheartening New Republic story in 2014 entitled "Public Health and Health Care Financing Choices Made AIDS an American Disease."

Opioid addiction is terrible - it changes the brain - and simply invoking willpower won't possibly be enough to help most addicts.   The criminalization of drug abuse has led addicts to share needles - with deadly results.  The US is alone among developed countries to be reluctant to provide needle exchange -  despite overwhelming evidence that this can decrease transmission of HIV and hepatitis and other blood borne diseases.

The Washington Post published an important article about drug abuse earlier this week   The hot spots for opioid addictions (which are mostly in deep red Appalachia and the midwest) are pretty much exactly where needle exchanges are least likely to be located.  This is good reason why we need an effective, evidence-based national approach to public health challenges like IV drug abuse.